On June 29, the American Association of Clinical Endocrinologists (AACE) announced that it would be arranging a clinical review of the potential link between diabetic ketoacidosis and SGLT2 Inhibitors. International and U.S. based experts, who are charged with the care and treatment of diabetes patients across the globe, will hold a conference in Dallas, Texas this October to answer questions from its membership raised in response to recent adverse event reports regarding this new class of diabetes drugs.
Type 2 diabetes treatments marketed as canagliflozin (Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance) may lead to dangerously high blood acid levels, according to the FDA, which issued a public safety communication on the topic this year.
Edelman, Krasin & Jaye remain concerned about the safety profile of SGLT2 inhibitors, especially given that the FDA continues to receive reports of ketoacidosis in patients treated with Farxiga, Invokana and Jardiance. If you or a loved one has suffered injury or adverse side effects from these medications, our knowledgeable diabetes drug lawyers are prepared to investigate your case to determine liability issues.
Product liability actions based on allegations of failure to warn and breach of warranty attempt to recover compensation for all related losses to the victim’s injury, including damages for past and future medical bills, lost income, loss of spousal consortium and pain and suffering. To learn more about your options for legal recourse following a diagnosis of ketoacidosis, we invite you to contact our offices for a free and confidential case evaluation.
Ketoacidosis reports logged by FDA
The AACE conference this fall will join diabetes experts, leading scientists and relevant medical professionals in the diabetes care arena to review data and provide recommendations for both prescribers and patients.
“AACE’s responsibility to its members and their diabetes patients is to conduct a complete, objective and balanced evaluation of the data and investigate any knowledge gaps before issuing our recommendations,” stated AACE President George Grunberger, MD, FACP, FACE in a press release, adding, “There are still unanswered questions to answer before we draw any definitive conclusions on the subject, and that is what this conference is designed to do.”
Ketoacidosis is a potentially life-threatening condition, where the blood becomes too acidic due to excess ketones. Early symptoms of this potential Invokana side effect include shortness of breath, nausea, vomiting, unusual fatigue, confusion and abdominal pain. Treatment entails a trip to the hospital or emergency room, where health care providers typically give glucose, insulin and intravenous fluids. If prompt medical attention isn’t sought by patients, ketoacidosis may lead to coma or even death.
In their May 15 drug safety communication, the FDA reported on at least 20 cases of diabetic ketoacidosis in patients taking SGLT2 inhibitors, in which all of the patients required hospitalization or emergency room treatment.
Invokana lawsuits seek just compensation
If you or a family member was hospitalized with ketoacidosis while taking an SGLT2 inhibitor, you may have grounds for demanding legal compensation. Invokana lawsuits are still in the development stage, as more patients are learning about the risks of this new type of diabetes medication. Here at Edelman, Krasin & Jaye, our attorneys have a demonstrable track record of successful outcomes in dangerous drug cases. Put our decades of experience and vast resources to work for you and your family.
We handle all claims on a contingency basis, which means you owe us nothing until we win or settle your case. To find out more about filing an Invokana or Farxiga lawsuit, please contact our offices at 1.800-469-7429.